{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:38:23Z","timestamp":1789749503150,"version":"4.0.1"},"reference-count":15,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2023,8]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Pyoderma gangrenosum currently lacks standardized therapy. New safer and more efficacious therapies are welcome.<\/jats:p>\n <\/jats:sec>\n \n Aims<\/jats:title>\n To present two new PG cases treated with JAK inhibitors, adding to the small existing experience<\/jats:p>\n <\/jats:sec>\n \n Methods & Methods<\/jats:title>\n Two case reports of PG patients successfully treated with tofacitinib and baricitinib.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Both patients were cured and presented no relapse. Patient # 1 used baricitinib 2 mg bid for 39 days while patient # 2 was treated with tofacitinib 5 mg bid for 120 days. No adverse reactions were seen.<\/jats:p>\n <\/jats:sec>\n \n Discussion<\/jats:title>\n The increasing usage of JAKi to treat inflammatory diseases had a positive reflex on PG therapy. Fifteen PG cases treated with these drugs had been found in literature and the two new cases here described add to the limited existing experience.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n This is a novel use of tofacitinib and baricitinib beyond the approved indications. JAKi are a welcome addition to our options to manage patients with PG.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/ijd.16676","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T03:23:40Z","timestamp":1682738620000},"page":"1088-1093","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum"],"prefix":"10.1111","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9134-9969","authenticated-orcid":false,"given":"Luiz G. M.","family":"Castro","sequence":"first","affiliation":[{"name":"Oncoderma S\u00e3o Paulo Brazil"},{"name":"Hospital Israelita Albert Einstein S\u00e3o Paulo Brazil"},{"name":"German Hospital Oswaldo Cruz S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,29]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164080"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100099"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102230.2012.04375.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.jfas.2013.07.003"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16468"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.10.047"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz015"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.07.035"},{"issue":"10","key":"e_1_2_8_10_1","first-page":"733","article-title":"Tofacitinib, a useful option for the treatment of pyoderma gangrenosum in an ulcerative colitis patient","volume":"113","author":"Olavarr\u00eda PS","year":"2021","journal-title":"Rev Esp Enferm Dig"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14683"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab005"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210457"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102927"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2016.09.003"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20936059"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.16676","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T14:54:11Z","timestamp":1700664851000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.16676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,29]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/ijd.16676"],"URL":"https:\/\/doi.org\/10.1111\/ijd.16676","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,29]]},"assertion":[{"value":"2022-07-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}